UC San Diego is one of several U.S. and Mexican institutions of higher education to join together and launch the CaliBaja Consortium for Higher Education with the goal of becoming a leader in cross-border education…
Epic’s circulating tumor cell analysis provides comprehensive, real-time information from a liquid biopsy that could help guide cancer treatments
SAN DIEGO, Feb. 26, 2015 /PRNewswire/ — Epic Sciences announced today that President and CEO Murali Prahalad, Ph.D. will present at the 35th Annual Cowen and Company Health Care Conference on Wednesday, March 4, 2015 at 10:00 a.m. EST in the MIT Room, 3rd Floor. The conference will be held at the Boston Marriott Copley Place Hotel in Boston, Mass.
Epic is developing diagnostic tests of high clinical utility to deliver real-time detection of genomic and proteomic changes that occur during the course of cancer treatments. From a simple blood test, Epic’s no cell left behind™ technology applies a global, unbiased approach to analyze all possible types of circulating tumor cells to match patients to singular or combination therapies or monitor and understand drug resistance.
About Epic Sciences
Epic Sciences, Inc. is developing novel diagnostics to personalize and advance the treatment and management of cancer. Epic’s mission is to enable the rapid and non-invasive detection of genetic and molecular changes in cancer throughout a patient’s journey. The company was founded on a powerful platform to identify and characterize rare cells, including circulating tumor cells (CTCs). Epic’s no cell left behind™ technology helps match patients to targeted therapies and monitor for drug resistance, so that the best treatment path can be chosen at every clinical decision point. Today, Epic has more than 30 collaborations with pharmaceutical companies and leading cancer research centers spanning 67 clinical studies. Epic’s goal is to commercialize our technology to increase the success rate of cancer drugs in clinical trials and improve patient outcomes by providing physicians real-time information to guide treatment choices.
SOURCE Epic Sciences
SOUTH SAN FRANCISCO, Calif., Feb. 26, 2015 /PRNewswire/ — CytomX, a biotechnology company developing Probody™ therapeutics for the treatment of cancer, today announced that Sean McCarthy, D. Phil., chief executive officer, will present a corporate overview at the upcoming Cowen and Company 35th Annual Health Care Conference in Boston. Dr. McCarthy’s presentation will take place at 4 p.m. EST on Monday, March 2.
About CytomX Therapeutics
CytomX Therapeutics develops Probody™ therapeutics for the treatment of cancer. Probodies are masked antibodies that remain inert in healthy tissue but are activated specifically in the disease microenvironment. The Probody approach is designed to blunt systemic toxicities associated with antibodies and expand the therapeutic window of these drugs, unlocking new therapeutic targets. The Company is initially focusing this highly innovative platform to discover and develop new immunotherapy and antibody drug conjugate therapies to treat areas of major unmet medical need in oncology. CytomX has attracted multiple strategic collaborations with industry-leading pharmaceutical companies including Pfizer Inc., ImmunoGen and Bristol-Myers Squibb. CytomX is led by a seasoned and proven management team and is financed by leading life science investors, including Third Rock Ventures, Canaan Partners, Roche Venture Fund and Pfizer Venture Investments. For more information, please visit www.cytomx.com.
SOURCE CytomX Therapeutics
LOS ANGELES, Feb. 26, 2015 /PRNewswire/ — Tauriga Sciences, Inc. (OTCQB: TAUG) (“Tauriga” or the “Company”), a diversified life sciences company with interests in the natural wellness sector and in developing a proprietary synthetic biology platform technology, announced today that its products will be featured at the SEC Compliance sponsor booth at the upcoming Roth Capital Partners’ 27th Annual Growth Stock Conference on March 8-11th at The Ritz Carlton, located at 1 Ritz Carlton Drive, Dana Point, California. One of the largest of its kind, ROTH’s investment conference brings together executives from close to 500 participating companies and over 3,000 attendees.
SEC Compliance, a leading filing agency registered with the Securities and Exchange Commission providing a full-service turnkey solution for regulatory requirements, is a co-sponsor of the conference and will be featuring TopiCanna, Tauriga’s proprietary topical medicinal cannabis cream, with the tagline, “Make it painless with SEC Compliance and Tauriga Sciences.”
Medicinal properties of cannabis are of great interest to the general and investing public, and many who have used topical cannabis creams have reported decreased musculoskeletal pain without psychoactive effects.
David McGuire, SEC Compliance CEO stated, “Our goal is to reduce the ‘pain’ and inconvenience of filing. SEC Compliance provides affordable and effective services for financial reporting and distribution by applying innovative technologies to improve productivity. Providing TopiCanna samples captures this idea in a clever and hopefully memorable way.”
“We are pleased to showcase Tauriga’s new natural wellness products to small cap and mid cap investors and other attendees at the Roth Capital Conference,” said Dr. Stella M. Sung, Chief Executive Officer. “In addition to TopiCanna, we will provide samples of our non-cannabis containing line of natural wellness dietary supplements.”
About SEC Compliance
SEC Compliance, Inc. (www.compliance-sec.com) has distinguished itself as a market leader of disclosure management solutions for publicly traded companies and others required by law to submit corporate information and financial statements electronically with the U.S. Securities and Exchange Commission.
From document EDGARization or XBRL Tagging to filing services and distribution, SEC Compliance provides qualified support and technical solutions that help companies streamline financial information while providing 20% cost-reductions guaranteed.
About Tauriga Sciences, Inc.:
Tauriga Sciences, Inc. (TAUG) is a diversified life sciences company focused on generating profitable revenues in the natural wellness sector and in developing a proprietary synthetic biology platform technology. The mission of the Company is to acquire and build a diversified portfolio of cutting edge technology assets that is capital efficient and of significant value to the shareholders. The Company’s business model includes the acquisition of licenses, equity stakes, rights on both an exclusive and non-exclusive basis, and entire businesses. Management is firmly committed to building lasting shareholder value in the short, intermediate, and long terms. Please visit the Company’s corporate website at www.tauriga.com and the Company’s e-commerce website at www.taurigastore.com.
This press release does not constitute an offer to sell or the solicitation of an offer to buy any of these securities, nor will there be any sale of these securities in any state or other jurisdiction in which such offer, solicitation or sale is not permitted. Any securities offered or issued in connection with the above-referenced merger and/or investment have not been registered, and will be offered pursuant to an exemption from registration.
Forward-Looking Statements: Except for statements of historical fact, this news release contains certain “forward-looking statements” as defined by the Private Securities Litigation Reform Act of 1995, including, without limitation expectations, beliefs, plans and objectives regarding the development, use and marketability of products. Such forward-looking statements are based on present circumstances and on TAUG’s predictions with respect to events that have not occurred, that may not occur, or that may occur with different consequences and timing than those now assumed or anticipated. Such forward-looking statements involve known and unknown risks, uncertainties and other factors, and are not guarantees of future performance or results and involve risks and uncertainties that could cause actual events or results to differ materially from the events or results expressed or implied by such forward-looking statements. Such factors include general economic and business conditions, the ability to successfully develop and market products, consumer and business consumption habits, the ability to fund operations and other factors over which TAUG has little or no control. Such forward-looking statements are made only as of the date of this release, and TAUG assumes no obligation to update forward-looking statements to reflect subsequent events or circumstances. Readers should not place undue reliance on these forward-looking statements. Risks, uncertainties and other factors are discussed in documents filed from time to time by TAUG with the Securities and Exchange Commission. This press release does not and shall not constitute an offer to sell or the solicitation of any offer to buy any of the securities, nor shall there be any sale of the securities, in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state. The securities have not been registered under the Securities Act of 1933, as amended (the “Securities Act”) or any state securities laws, and may not be offered or sold in the United States absent registration, or an applicable exemption from registration, under the Securities Act and applicable state securities laws.
SOURCE Tauriga Sciences, Inc.
Fast growing Biotech company-well-rounded PHP Engineer! Based in the beautiful heart of San Diego, we are a successful … verification document form upon hire. Fast growing Biotech company-well-rounded PHP Engineer! Based in the…
Details: Research Associate – Wet Lab 6 Month Contract Position- H-1’s/Subcontractors will NOT be considered: As a Research Associate you will work in a dynamic, team-oriented environment and help create genomic analysis tools used in the leading edge …
Details: Ref ID: 00680-9732147 Classification: Attorney-licensed II 4-9 yrs exp Compensation: $150,000.00 to $180,000.00 per year RHL has an immediate permanent opportunity for a Patent Attorney that is licensed in California and admitted to the USPTO …
Details: Responsibilities Communicate with other Planner Schedulers to ensure schedules, work orders, campaigns, and materials are in alignment to support the manufacturing process Perform production and maintenance scheduling activities (order management) within SAP PP/DS and APO Understand SAP ERP master data and dependencies Production activity controls utilizing the planning/inventory control system Trouble shoot SAP system issues and assist stakeholders with emergent events requiring order management support Respond to emergent events to support stakeholders groups to resume production and attain MPS Coordinate planning and dispensing activities with multiple groups across sites Communicate and resolve scheduling conflicts and constraints effectively Communicate and resolve materials issues and shortages effectively Review & approve non-production material requests and/or production orders based upon the established guidelines Build collaborative relationship and interact with departments such as MIG, Manufacturing, Material Operations and Regional Material Planners that are supported in the raw material scheduling function to understand needs or requirements Perform materials planning and forecasting activities Review and ensure material requirements plan accuracy and resolve any inventory availability issues Collectively work to identify materials, detailed scheduling and inventory management process improvements to reduce costs or increase efficiencies Review stock transfer requests and converts into order considering factors such as available, excess, network allocation, expiring inventories; vendor change items, manufacturing and storage requirements Assists in obtaining, organizing information and conducting raw materials supply /demand relevant data analysis Track and develop metrics associated with planning, forecasting, schedule adherence, and inventory accuracy Assist with other operations associated with the planning and scheduling automation systems Assist with business system development Follows established safety and environmental guidelines and procedures for all work performed Immediately reports safety and environmental incidents including injuries, illnesses, near misses, and safety suggestions Fosters a positive safety culture in which no one gets hurt
HCR is a full-service international contract research organization with a successful two-decade track record supporting biotechnology, medical device and…
From SynteractHCR, Inc. – 26 Feb 2015 03:56:01 GMT
– View all San Dieg…
Incumbent will work with departments and departmental leadership to ensure space solution meets departmental goals, facilitate planning and programming meetings…
From Illumina, Inc. – 26 Feb 2015 02:21:26 GMT
– View all San D…